Literature DB >> 26464363

[Chemotherapy with paclitaxel leads to microRNA release].

R Maushagen1, R Pries, B Wollenberg.   

Abstract

BACKGROUND: During recent years, microRNAs (Greek: micros = small; miRNA) have become more important. miRNAs are highly conserved, noncoding, single-stranded RNA molecules 17–28 nucleotide in length. Secreted by tumor cells, miRNAs regulate many biological processes and are also involved in chemoresistance. Classical forms of cancer treatment lead to miRNA release. Which miRNAs are correlated to head and neck squamous cell carcinomas (HNSCC) and their chemoresistance to paclitaxel remains unknown.
OBJECTIVES: Identification of miRNAs expressed in HNSCC and elucidation of those involved in conferring chemoresistance to paclitaxel.
MATERIALS AND METHODS: To identify changes in gene expression, HNSCC cell lines were treated with 10 μM paclitaxel for 48 h and analyzed by microarray analysis. Thereafter, changed in expression of single miRNAs (miR221*, miR222 and miR222*) following paclitaxel treatment were analyzed using a quantitative real-time polymerase chain reaction (qRT-PCR).
RESULTS: Under treatment with paclitaxel, miRNAs were released. The dominant change is upregulation of MIR222 gene expression. Regulation of miR222* expression under paclitaxel treatment seems to be different in human papillomavirus (HPV)-negative and HPV-positive HNSCC cell lines.
CONCLUSION: Expression of mirR221/222 is correlated to cell cycle regulation, carcinogenesis, and chemoresistance. Detailed knowledge of the molecular mechanisms and effects ofmiRNAs is important for identifying miRNAs as cancermarkers, as well as for increasing the efficiency of cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26464363     DOI: 10.1007/s00106-015-0080-z

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  26 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker.

Authors:  Hisashi Kanemaru; Satoshi Fukushima; Junji Yamashita; Noritoshi Honda; Rie Oyama; Asako Kakimoto; Shinichi Masuguchi; Tsuyoshi Ishihara; Yuji Inoue; Masatoshi Jinnin; Hironobu Ihn
Journal:  J Dermatol Sci       Date:  2011-01-13       Impact factor: 4.563

3.  Quantification of mRNA using real-time RT-PCR.

Authors:  Tania Nolan; Rebecca E Hands; Stephen A Bustin
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

4.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs.

Authors:  Lee P Lim; Nelson C Lau; Philip Garrett-Engele; Andrew Grimson; Janell M Schelter; John Castle; David P Bartel; Peter S Linsley; Jason M Johnson
Journal:  Nature       Date:  2005-01-30       Impact factor: 49.962

5.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

6.  Extensive modulation of a set of microRNAs in primary glioblastoma.

Authors:  S A Ciafrè; S Galardi; A Mangiola; M Ferracin; C-G Liu; G Sabatino; M Negrini; G Maira; C M Croce; M G Farace
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

7.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

Authors:  Michela Garofalo; Gianpiero Di Leva; Giulia Romano; Gerard Nuovo; Sung-Suk Suh; Apollinaire Ngankeu; Cristian Taccioli; Flavia Pichiorri; Hansjuerg Alder; Paola Secchiero; Pierluigi Gasparini; Arianna Gonelli; Stefan Costinean; Mario Acunzo; Gerolama Condorelli; Carlo Maria Croce
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

8.  The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.

Authors:  Tong Sun; Qianben Wang; Steven Balk; Myles Brown; Gwo-Shu Mary Lee; Philip Kantoff
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

9.  MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle.

Authors:  Rosa Visone; Lucia Russo; Pierlorenzo Pallante; Ivana De Martino; Angelo Ferraro; Vincenza Leone; Eleonora Borbone; Fabio Petrocca; Hansjuerg Alder; Carlo Maria Croce; Alfredo Fusco
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

10.  Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts.

Authors:  Wenxia Meng; Qingjie Xia; Lanyan Wu; Sixiu Chen; Xin He; Lin Zhang; Qinghong Gao; Hongmei Zhou
Journal:  BMC Cancer       Date:  2011-02-28       Impact factor: 4.430

View more
  1 in total

Review 1.  New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies.

Authors:  Erika Larrea; Carla Sole; Lorea Manterola; Ibai Goicoechea; María Armesto; María Arestin; María M Caffarel; Angela M Araujo; María Araiz; Marta Fernandez-Mercado; Charles H Lawrie
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.